Phaseline

Companies › vTv Therapeutics

vTv Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cadisegliatin
Glucokinase activator
GCKPhase 3Diabetes Mellitus, Type 1Apr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06334133CadisegliatinPhase 3Diabetes Mellitus, Type 1Metabolic and endocrineApr 2027

From the company's SEC filings

Cash of $77m on 2026-09-30; operating cash outflow about $17m a year; runway about 55 months at that burn, to May 2031; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

GCK (1)

Companies with the same targets

AstraZeneca

Companies built like this

Calcilytix Therapeutics, Inc., a BridgeBio company Medicure Vogenx Fresenius Kabi Renibus Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.